PerkinElmer and Waters Announce Collaboration for Advanced Neonatal Screening Solutions.

BOSTON -- PerkinElmer Inc. (NYSE: PKI), the world's leading provider of neonatal screening systems and Waters Corporation (NYSE: WAT), a premier supplier of mass spectrometers have entered into a long-term collaboration with a reagent/software/mass spectrometry/liquid chromatography platform to deliver advanced newborn screening solutions.

Through this agreement, PerkinElmer will become the exclusive distributor of the Waters(R) Quattro micro(TM) and Waters Quattro Premier (TM) MS/MS platforms and the Alliance(R) HPLC System for neonatal screening applications. Newborn screening for metabolic disorders has become one of the most widely accepted procedures in preventative pediatrics. In August 2004, PerkinElmer became the only company in the world to receive clearance from the U.S. Food and Drug Administration for its Neogram(R) Tandem Mass Spectrometry Kit (TMS). PerkinElmer's TMS system is helping to drive the global standardization of metabolic screening with the capability to analyze more than 40 disease markers with a single blood sample. Early detection increases treatment and management options, leading to an improved quality of life. PerkinElmer provides a complete screening solution from sample collection to results reporting.

"We are pleased to collaborate with Waters on their mass spectrometry technologies in our integrated solutions for newborn screening," said Peter B. Coggins, Ph.D., president of PerkinElmer Life & Analytical Sciences. "Through this agreement, our mutual goal is to ensure a pipeline of advanced and integrated products that protect the health of newborns. We are excited about our growth prospects in this area, and remain committed to supporting all existing customer equipment configurations."

"We are excited to deliver our market leading mass spectrometry technologies into the high-growth neonatal screening markets. This partnership with PerkinElmer will help speed the development and release of products to enable early intervention and treatment thereby improving the health of newborns, lower healthcare costs and save lives," said Michael Yelle, Senior Director - Clinical Business Operations at Waters Corporation. "PerkinElmer has broad knowledge and experience in the field of newborn screening, especially in the development and manufacture of reagents and application software, while Waters provides market-leading, high-quality tandem mass spectrometers."

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments, including, without limitation, all projections of future financial results, are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important risk factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including, without limitation, economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries, risks related to our failure to introduce new products in a timely manner, the impact of our debt on our cash flow and investment opportunities, our ability to comply with financial covenants contained in our credit agreements and debt instruments, cyclical downturns continuing to affect several of the industries into which we sell our products, our ability to adjust our operations to address unexpected changes, our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business, the loss of any of our licenses that may require us to stop selling products or lose competitive advantage, competition, regulatory compliance, regulatory changes, our failure to obtain and enforce intellectual property protection, our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets, as well as other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q, each on file with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Industrial Sciences markets to improve the quality of life. The Company reported revenues of $1.7 billion in 2004, has 10,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

Waters Corporation holds worldwide leading positions in three complementary analytical technologies - liquid chromatography, mass spectrometry and thermal analysis. These markets account for $4.5 - $5.0 billion of the overall $20 + billion analytical instrument market.

Waters, Alliance, Quattro micro, and Quattro Premier are trademarks of Waters Corporation.